Statera Biopharma and Immune Therapeutics Inc. Announce Strategic Agreement for Rights to Low Dose Naltrexone. Potential indication payments will include asthma, multiple sclerosis, HIV and chemotherapy. In aggregate, this transaction has the ability to generate over $400 million in non-dilutive payments to Statera.
Trading within the channel continues. No shares available at the moment to short. Very risky going against the stock. Looking very Bullish in the immediate short term and long term. Of note, competitors $TWTR and $FB are down tremendous.
Trading within the channel continues. No shares available at the moment to short. Very risky going against the stock. Looking very Bullish in the immediate short term and long term. Of note, competitors $TWTR and $FB are down tremendous.
Small market cap stock DWAC to merge with TMTG. Currently sitting around ($3B) with the potential to draw 200M person audience.. Yeah this is going to land between $20B and $40B Market cap no problem. My only concern is the shares that will flood the market once the merger goes through. Let me know your thoughts.
